Screening for prostate cancer: opportunities and challenges

Area of Science:

• Urology
• Oncology
• Biomarker Discovery

Background:

• Prostate-specific antigen (PSA) testing and digital rectal examination are standard for prostate cancer risk assessment in the U.S.
• Millions of men expect annual PSA screening, and physicians rely on this method.
• Current PSA interpretation is complex and cannot be a simple yes/no determination.

Purpose of the Study:

• To highlight the limitations of current prostate cancer screening methods.
• To emphasize the need for integrating multiple risk factors into PSA interpretation.
• To discuss the future of prostate cancer screening with novel biomarkers.

Main Methods:

• Review of current prostate cancer screening practices and interpretation of PSA levels.
• Discussion of integrating individual risk factors (ethnicity, family history, risk aversion) with PSA values.
• Exploration of the development and validation of new biomarkers for prostate cancer risk prediction.

Main Results:

• PSA levels must be interpreted alongside other individual risk factors.
• New biomarkers are crucial for advancing prostate cancer risk prediction.
• Validation studies for new biomarkers must include prognostic measures due to high cancer incidence.

Conclusions:

• Prostate cancer screening requires a multifactorial approach beyond PSA alone.
• The development of biomarkers that accurately distinguish aggressive from indolent disease is a critical goal.
• Future screening strategies will incorporate validated biomarkers for precise risk assessment and prognosis.